These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33580867)

  • 21. Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort.
    Tao L; Wilson EC; Griffin SJ; Simmons RK;
    Value Health; 2013; 16(6):1074-80. PubMed ID: 24041358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
    Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
    ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of prediction models for cardiovascular and mortality risk in people with type 2 diabetes: An external validation in 23 685 adults included in the UK Biobank.
    Zhang Y; Jiong OX; Tang S; Tang YC; Wong CT; Ng CS; Quan J
    Diabetes Obes Metab; 2024 May; 26(5):1697-1705. PubMed ID: 38297974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
    Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model.
    McEwan P; Ward T; Bennett H; Bergenheim K
    Cost Eff Resour Alloc; 2015; 13():12. PubMed ID: 26244041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
    Zhou Z; Lindley RI; Rådholm K; Jenkins B; Watson J; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Shaw W; Oh R; Desai M; Matthews DR; Neal B
    Stroke; 2019 Feb; 50(2):396-404. PubMed ID: 30591006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Diabetes Ther; 2020 Nov; 11(11):2657-2676. PubMed ID: 32930969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canagliflozin and Cardiovascular disease- results of the CANVAS trial.
    Shah SR; Najim NI; Abbasi Z; Fatima M; Jangda AA; Shahnawaz W; Shahid M; Shah SA
    J Community Hosp Intern Med Perspect; 2018; 8(5):267-268. PubMed ID: 30357039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
    Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR;
    Diabetes Obes Metab; 2017 Jul; 19(7):926-935. PubMed ID: 28244644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
    Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
    Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
    J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
    [No Abstract]   [Full Text] [Related]  

  • 35. Canagliflozin review - safety and efficacy profile in patients with T2DM.
    Jakher H; Chang TI; Tan M; Mahaffey KW
    Diabetes Metab Syndr Obes; 2019; 12():209-215. PubMed ID: 30787627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
    Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B
    Int J Cardiol; 2020 Nov; 318():126-129. PubMed ID: 32569700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):149-153. PubMed ID: 29297732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
    Willis M; Asseburg C; He J
    J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
    J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.